Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109 [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104]
Corresponding Author of This Article
Ho Sup Lee, MD, Department of Internal Medicine, Kosin University College of Medicine, 34 Amnam-Dong, Seo-Gu, Busan 602-703, South Korea. hs52silver@gmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109 Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
Lee Chun Park, Ho Sup Lee, Seong Hoon Shin, Seun Ja Park, Moo In Park, Sung Yong Oh, Hyuk Chan Kwon, Jin ho Baek, Young Jin Choi, Myoung Joo Kang, Yang Soo Kim
Lee Chun Park, Ho Sup Lee, Seong Hoon Shin, Seun Ja Park, Moo In Park, Yang Soo Kim, Department of Internal Medicine, Kosin University College of Medicine, Busan 602-703, South Korea
Sung Yong Oh, Hyuk Chan Kwon, Department of Internal Medicine, Dong-A University Hospital, Busan 602-715, South Korea
Jin ho Baek, Department of Internal Medicine, Ulsan University Hospital, Ulsan 682-714, South Korea
Young Jin Choi, Department of Internal Medicine, Busan National University Hospital, Busan 626-770, South Korea
Myoung Joo Kang, Department of Internal Medicine, Busan Paik Hospital, Busan 614-735, South Korea
Author contributions: Park LC and Lee HS collected and analyzed the clinical data, designed the study and wrote the manuscript; Shin SH and Kim YS contributed to the conception of the study; Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ and Kang MJ collected the clinical data; Lee HS was involved in revising the manuscript critically for intellectual content and gave final approval for the submission of the manuscript.
Correspondence to: Ho Sup Lee, MD, Department of Internal Medicine, Kosin University College of Medicine, 34 Amnam-Dong, Seo-Gu, Busan 602-703, South Korea. hs52silver@gmail.com
Telephone: +82-51-9906107 Fax: +82-51-9905820
Received: July 1, 2011 Revised: January 12, 2012 Accepted: February 8, 2012 Published online: March 14, 2012
Abstract
AIM: To determine the efficacy of bevacizumab in patients with metastatic colorectal cancer (MCRC) who have failed prior chemotherapy without bevacizumab.
METHODS: Between March 2002 and June 2010, 40 patients in South Korea with MCRC who were treated with bevacizumab plus chemotherapy as a second or later-line treatment were analyzed retrospectively for their overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The tumor responses were assessed using the Response Evaluation Criteria in Solid Tumors guidelines.
RESULTS: All of the patients had progressed under prior chemotherapy without bevacizumab. Three patients (7.5%) exhibited an ORR, twenty one patients (52.5%) exhibited stable disease (SD), and fifteen patients (37.5%) exhibited disease progression. The median duration of the OS and PFS were 14.0 mo and 6.13 mo respectively. The median OSs were 16.60, 14.07 and 13.00 mo for second-line, third-line and fourth- or later-line treatments, respectively. The median PFSs were 7.23, 7.30 and 3.87 mo for the second-line, third-line and fourth- or later-line treatments, respectively.
CONCLUSION: In patients with MCRC, bevacizumab combined chemotherapy may be beneficial during second- or later-line treatment.
